UNSPSC 51171838: Fosaprepitant or ivemend

This classification denotes an antiemetic agent with the molecular formula C23H22F7N4O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L8OF9XRDC. European Medicines Agency schedules fosaprepitant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25384. The term FOSAPREPITANT is an International Non-Proprietary Name. Fosaprepitant or ivemend bears US NLM identifiers UMLS ID C2349941 and NCI Concept Code C72787.

SMILES: CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NC(=O)N(N3)P(=O)(O)O)C4=CC=C(C=C4)F.

UNSPSC 51171838 Fosaprepitant or Ivemend, a Commodity code, encompasses pharmaceutical products procured by state and local health agencies, criminal justice systems, and multistate cooperative purchasing vehicles. State and local governments buy branded and generic antiemetic medications under this code through centralized pharmaceutical contracting frameworks, direct-to-manufacturer relationships, and cooperative group purchasing agreements. Recent activity shows solicitations spanning drug testing program support, therapeutic pharmacy initiatives, and multistate generic pharmaceutical supply contracts.

Activity under the code involves state health commissions, county criminal justice departments, and multistate cooperative purchasing alliances. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative procurement models for pharmaceutical supply. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with cGMP and DSCSA requirements. Collin County Community Supervision and Corrections Department in Texas posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 over two years and three optional one-year renewals. MMCAP contracts span participating state and local facilities in Minnesota and Oregon, while Texas procurement activity reflects both state health system and county-level demand. Recent opportunities show increasing use of cooperative purchasing mechanisms and exploration of direct manufacturer relationships as alternatives to traditional wholesale distribution models.